Unexpected antibody distribution among tumor patients: analysis of 111 483 cases
10.13303/j.cjbt.issn.1004-549x.2023.09.011
- VernacularTitle:111 483例肿瘤患者意外抗体的分布及特点
- Author:
Haiyu ZHANG
1
,
2
;
Ke ZHANG
1
;
Hongzhou WU
3
;
Lijun ZHONG
4
;
Zuo WANG
1
;
Guihua ZHANG
1
;
Yannan FENG
1
;
Li CHEN
1
;
Lian DAI
1
;
Shanshan WAN
1
Author Information
1. Department of Transfusion, Sichuan Cancer Hospital, Chengdu 610041, China
2. Department of Biomedical Engineering, University of Electronic Science and Technology of China
3. Department of Biomedical Engineering, University of Electronic Science and Technology of China
4. Library, Sichuan Cancer Hospital, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
tumor;
blood transfusion history;
unexpected antibody screening;
antibody identification
- From:
Chinese Journal of Blood Transfusion
2023;36(9):803-806
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the distribution of unexpected antibodies in tumor patients retrospectively and explore the clinical significance. 【Methods】 Unexpected antibody screening was performed on inpatients with blood preparation and blood transfusion in our hospital from January 2004 to December 2022, with 1 176 cases tested positive, and the types of unexpected antibodies and distribution characteristics were statistically analyzed. 【Results】 Unexpected antibodies were screened in 1 176 cases, with the positive rate at 1.05% (1 176/111 483). The unexpected antibodies were mainly anti-E 16.33%(192/1 176), anti-M 7.99% (94/1 176), anti-Mur 5.70% (67/1 176) and anti-Lea 4.76% (56/1 176). Among the 1 176 cases, gastrointestinal tumors accounted for 27.99% (329/1 176), gynecological tumors accounted for 24.84% (292/1 176), respiratory tumors accounted for 16.67% (196/1 176) . 【Conclusion】 The influencing factors of unexpected antibodies in tumor patients were disease type, blood transfusion history and blood type. Therefore, it is necessary for clinical departments to carry out unexpected antibody screening and perform Rh blood type matched transfusion for tumor patients to avoid alloantibody production.
